Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP

NCT07589699 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

59

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
HER2-positive Breast Cancer
Early-stage Breast Cancer
Locally Advanced Breast Cancer

Interventions

DRUG: Trastuzumab Rezetecan

Sponsor

The First Affiliated Hospital with Nanjing Medical University